Literature DB >> 11246620

Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.

S Campbell1, S Ghosh.   

Abstract

Treatment of Crohn's disease with infliximab is an important drug therapy for patients with refractory and fistulating disease. There are concerns over its use in a proportion of Crohn's patients with concurrent hepatitis C infection, since there are theoretical risks of accelerated hepatic decompensation due to the immunomodulatory impact of infliximab. We report a patient with both Crohn's disease and ongoing active hepatitis C infection who underwent infliximab therapy, with no worsening of his liver function or PCR status.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11246620     DOI： 10.1097/00042737-200102000-00016

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN： 0954-691X            Impact factor:   2.566


  11 in total

1.  Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Authors:  Yoshitaka Ueno; Shinji Tanaka; Masaru Shimamoto; Yoshihiro Miyanaka; Toru Hiyama; Masanori Ito; Yasuhiko Kitadai; Masaharu Yoshihara; Masaharu Sumii; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

3.  Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.

Authors:  Alina M Allen; W Ray Kim; Joseph Larson; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 4.  Hepatitis C virus and inflammatory bowel disease.

Authors:  Todd L Horn; Joel Reynolds; Willem de Villiers; Luis R Peña
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

5.  Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.

Authors:  M Esteve; C Saro; F González-Huix; F Suarez; M Forné; J M Viver
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

Review 6.  The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.

Authors:  Ming Valerie Lin; Wojciech Blonski; Anna M Buchner; K Rajender Reddy; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-11-20       Impact factor: 3.199

Review 7.  Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review.

Authors:  Maurizio Pompili; Marco Biolato; Luca Miele; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 8.  Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.

Authors:  Stefano Sansone; Maria Guarino; Fabiana Castiglione; Antonio Rispo; Francesco Auriemma; Ilaria Loperto; Matilde Rea; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

9.  Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors:  J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 10.  Infectious etiology of vasculitis: diagnosis and management.

Authors:  Niveditha Mohan; Gail Kerr
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.